Key result
Low-dose recombinant Factor VIIa reversed warfarin anticoagulation to a goal INR of 1.5 or less in 71.9% of patients compared to 33.8% of patients receiving 3-factor prothrombin complex concentrate.
Why the study?
Does low-dose recombinant Factor VIIa improve achievement of INR <= 1.5 compared to 3-factor prothrombin complex concentrate in patients requiring emergent warfarin reversal?
Cohort (n=106)
No
Does low-dose recombinant Factor VIIa improve achievement of INR <= 1.5 compared to 3-factor prothrombin complex concentrate in patients requiring emergent warfarin reversal?
Low-dose recombinant Factor VIIa was more effective than 3-factor prothrombin complex concentrate at achieving a goal INR of 1.5 or less for emergent warfarin reversal, with similar rates of thromboembolic events.
Answers are grounded in this paper and cite their sources.
Low-dose rFVIIa was associated with higher INR reversal rates; should not yet change practice pending randomized trials.
INTRODUCTION: Prothrombin complex concentrate (PCC) and recombinant Factor VIIa (rFVIIa) have been used for emergent reversal of warfarin anticoagulation. Few clinical studies have compared these agents in warfarin reversal. We compared warfarin reversal in patients who received either 3 factor PCC (PCC3) or low-dose rFVIIa (LDrFVIIa) for reversal of warfarin anticoagulation. METHODS: Data were collected from medical charts of patients who received at least one dose of PCC3 (20 units/kg) or LDrFVIIa (1000 or 1200 mcg) for emergent warfarin reversal from August 2007 to October 2011. The primary end-points were achievement of an INR 1.5 or less for efficacy and thromboembolic events for safety. RESULTS: Seventy-four PCC3 and 32 LDrFVIIa patients were analyzed. Baseline demographics, reason for warfarin reversal, and initial INR were equivalent. There was no difference in the use of vitamin K or fresh frozen plasma. More LDrFVIIa patients achieved an INR of 1.5 or less (71.9% vs. 33.8%, p =0.001). The follow-up INR was lower after LDrFVIIa (1.25 vs. 1.75, p < 0.05) and the percent change in INR was larger after LDrFVIIa (54.1% vs. 38.8%, p = 0.002). There was no difference in the number of thromboembolic events (2 LDrFVIIa vs. 5 PCC3, p = 1.00), mortality, length of hospital stay, or cost. CONCLUSIONS: Based on achieving a goal INR of 1.5 or less, LDrFVIIa was more likely than PCC3 to reverse warfarin anticoagulation. Thromboembolic events were equivalent in patients receiving PCC3 and LDrFVIIa.
No takes yet. Share an insight, caveat, or question.
Chapman et al. (2014) conducted a cohort in Warfarin anticoagulation reversal for emergent bleeding (n=106). Low-dose recombinant Factor VIIa (LDrFVIIa) vs. 3-factor prothrombin complex concentrate (PCC3) 20 units/kg was evaluated on Achievement of an INR 1.5 or less (p=0.001). Low-dose recombinant Factor VIIa reversed warfarin anticoagulation to a goal INR of 1.5 or less in 71.9% of patients compared to 33.8% of patients receiving 3-factor prothrombin complex concentrate.
Synapse has enriched 10 related papers. Consider them for comparative context: